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Somatostatin receptors expressed on tumor cells form the
rationale for somatostatin analog treatment of patients with
somatostatin receptor-positive neuroendocrine tumors. Nev-
ertheless, although somatostatin analogs effectively control
hormonal hypersecretion by GH-secreting pituitary adeno-
mas, islet cell tumors, and carcinoid tumors, significant dif-
ferences are observed among patients with respect to the ef-
ficacy of treatment. This may be related to a differential
expression of somatostatin receptor subtypes among tumors.
In addition, the property of somatostatin receptor subtypes to
undergo agonist-induced internalization has important con-
sequences for visualizing, as well as for therapy, of receptor-
postive tumors using radioisotope- or chemotherapeutic-
compound-coupled somatostatin analogs. This review covers
the pathophysiological role of somatostatin receptor subtypes
in determining the efficacy of treatment of patients with so-
matostatin receptor-positive tumors using somatostatin ana-
logs, as well as the preclinical and clinical consequences of
agonist-induced receptor internalization for somatostatin
receptor-targeted radio- and chemotherapy. Herein, the de-
velopment and potential role of novel somatostatin analogs is
discussed. (Endocrine Reviews 24: 28–47, 2003)
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I. General Introduction
SINCE ITS DISCOVERY in 1973 by Guillemin and Gerich(1), knowledge of the functional role of somatostatin
(SS) in regulating neurotransmission in the brain, as well as
in the regulation of secretion processes in the anterior pitu-
itary gland, the pancreas, and the gastrointestinal tract, has
increased considerably. In addition to playing an important
regulatory role in neurotransmission and secretion, the pep-
tide may control cell proliferation in normal and tumorous
tissues as well (2, 3). Between 1992 and 1994, five SS receptor
(sst) subtype genes were cloned and characterized; they were
code-named sst1, sst2, sst3, sst4, and sst5 (4). The discovery of
these genes initiated a large number of studies directed to
elucidate their expression in SS-target tissues, their selectiv-
ity of binding of structural SS-analogs, and their coupling to
the different second messenger systems known to be acti-
vated upon SS binding to its receptor. This has been reviewed
extensively (5–9). The discovery of the sst subtype genes also
initiated the development of a large series of novel SS-
analogs that selectively bind to sst subtypes. Currently, a
number of these sst subtype-selective analogs are being
tested for their in vivo and in vitro potencies to modulate
hormone secretion and/or cell proliferation (8, 10). The high
density of SS receptors on human neuroendocrine tumors
originating from normal SS target tissues has been used
clinically to treat symptoms of hormonal hypersecretion in
patients with GH- or TSH-secreting pituitary adenomas, as
well as in patients harboring islet cell or carcinoid tumors
with SS-analogs (11). However, although SS-analogs effec-
tively control hormonal hypersecretion by neuroendocrine
tumors, their effects are often transient, and considerable
differences between patients harboring islet cell and carci-
noid tumors exist with respect to the development of tachy-
phylaxis. In addition, the presence of a high density of SS
receptors on human neuroendocrine tumors has allowed the
development in 1989 (2, 12) of the technique of sst scintig-
raphy using radiolabeled SS-analogs to visualize sst-positive
tumors in vivo (2, 13).
The above physiological and pathophysiological roles of
SS and the presence of SS receptors on neuroendocrine tu-
mors have been reviewed extensively. Much less attention
has been paid to the clinical importance of sst internalization
in determining the uptake of radiolabeled SS-analogs by
sst-positive neuroendocrine tumors and the role of individ-
ual sst subtypes herein, as well as to the mechanisms in-
Abbreviations: CHO, Chinese hamster ovary; DOTA, tetraazacy-
clododecane tetraacetic acid; DTPA, diethylenetriamine pentaacetic
acid; hsst, human sst; 5-HIAA, 5-hydroxyindolacetic acid; 177Lu, 177lu-
tetium; MTC, medullary thyroid carcinoma; PRL, prolactin; SS, soma-
tostatin; sst, SS receptor; wt, wild-type; 90Y, yttrium-90.
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volved in tachyphylaxis to SS-analog therapy. This manu-
script gives an overview of the current knowledge on the
internalization and cellular uptake of radiolabeled SS-
analogs by sst-positive tumor cells and the involvement of
endogenously expressed sst subtypes in this process, as well
as the clinical consequences of sst internalization for sst-
targeted radio- or chemotherapy. Section III of this review
addresses the potential mechanisms involved in tachyphy-
laxis after long-term treatment of patients with neuroendo-
crine tumors with SS-analogs.
A. SS and sst subtypes
SS is a small cyclic peptide that is widely expressed
throughout the central nervous system and peripheral tis-
sues. In peripheral tissues, SS exerts predominantly inhibi-
tory actions (14) on secretion processes, whereas the peptide
acts as a neurotransmitter in both a stimulatory and inhib-
itory manner in the brain (15). SS is formed by proteolytic
processing of larger precursor molecules, i.e., prepro-SS and
pro-SS. After cleavage of the pro-SS molecule, two biologi-
cally active forms of SS consisting of 14 (SS-14) or 28 (SS-28)
amino acids are generated (16). SS-14 and SS-28 act via high-
affinity G protein-coupled membrane receptors. Five sst sub-
types have been cloned and characterized. The genes encod-
ing the five sst subtypes are localized on different
chromosomes (8). Via alternative splicing, two forms of the
sst2 receptor can be generated, i.e., sst2A and sst2B (17, 18). The
only difference between sst2A and sst2B is the length of their
cytoplasmic tail. The five sst subtypes share a coupling to the
second messenger systems known to be activated upon SS
binding to its receptor. These systems include inhibition of
adenylyl cyclase activity and activity of calcium channels, as
well as stimulation of phosphotyrosine phosphatase or
MAPK activity. This has been reviewed extensively (7–9).
Although the inhibitory effects on adenylate cyclase activity
and on the influx of Ca2 are linked to inhibition of secretion
processes, the activation of phosphotyrosine phosphatase or
MAPK activity may play a role in the regulatory effects that
SS exerts on cell proliferation (2, 3, 10). The selective induc-
tion of apoptosis mediated via activation of sst3 receptors is
of particular interest in this respect. The role of the individual
sst subtypes and the mechanism of action of the antiprolif-
erative effects by SS have been reviewed recently (9). The five
sst subtypes all bind SS-14 and SS-28 with high affinity but
can be divided into two subclasses on their ability to bind
structural octapeptide analogs of SS. The sst1 and sst4 recep-
tors do not bind octapeptide SS-analogs, whereas sst2A, sst3,
and sst5 receptors display a high, low, and moderate affinity,
respectively, toward octapeptide SS-analogs such as the clin-
ically used octreotide and lanreotide (Table 1).
B. SS receptor subtype expression in normal and
tumorous human tissues
Classical SS-target tissues such as the central nervous sys-
tem, the anterior pituitary gland, and the pancreas express
multiple sst subtypes. The expression of sst subtypes in the
brain has only been studied extensively in rodent species. In
the brain, mRNAs encoding for all five sst subtypes are
expressed in a highly specific pattern (8). This regional, char-
acteristic expression pattern of sst subtypes in the brain has
recently been confirmed at the protein level by immunohisto-
chemical techniques using sst subtype-specific antibodies
(19). The adult human pituitary gland expresses sst1, sst2,
sst3, and sst5 mRNAs, but not sst4 mRNA (20). In addition,
human pancreatic islet cells express all five sst subtype pro-
teins, as determined by immunohistochemistry (21, 22). In
human islets, sst1, sst2, and sst5 receptors are the most abun-
dantly expressed subtypes, with a high percentage of -cells
expressing sst1 and sst5, -cells expressing sst2, and -cells
expressing sst5 (22).
Neuroendocrine tumors, which often originate from SS-
target tissues, frequently express a high density of SS recep-
tors (23–26). The sst-expressing human tumors include
pituitary adenomas, islet cell tumors, carcinoids, para-
gangliomas, pheochromocytomas, small cell lung cancers,
and medullary thyroid carcinomas (MTCs), but also breast
cancers and malignant lymphomas (24, 27). The sst subtype
expression in different types of human cancers has been
demonstrated at the mRNA level using in situ hybridization
(28, 29), RNase protection assays, and RT-PCR (20, 27, 30–34).
The majority of human sst-positive tumors simultaneously
express multiple sst subtypes, although there is a consider-
able variation in sst subtype expression between the different
tumor types and among tumors of the same type. Table 2
shows that sst2 is the most abundantly expressed receptor
subtype in the majority of tumors. Recent studies using an-
tibodies raised against synthetic peptide sequences of the
sst1, sst2, sst3, and sst5 receptor confirmed this variation in the
expression of sst subtypes in different types of human tu-
mors (Table 2; Refs. 35–38). The higher number of tumors
expressing particular sst subtype mRNAs, compared with
the number of tumors expressing sst subtype proteins, may
be related to the higher sensitivity of techniques such as
RT-PCR compared with immunohistochemistry. On the
other hand, techniques such as RT-PCR might overestimate
the real percentage of tumors expressing sst subtypes be-
cause blood vessels, immune cells, stromal and contaminat-
ing normal cells, which are present in or surround human
tumors, may express sst subtypes as well (29, 39–41). The
predominant expression of sst2 receptors in human tumors
forms the basis for the successful clinical application of oc-
tapeptide SS-analogs such as octreotide and lanreotide in
controlling symptoms related to hormonal hypersecretion in
patients with GH-secreting pituitary adenomas, islet cell tu-
TABLE 1. SS receptor subtype selectivity of binding of SS agonists
Agonist
Binding potency (IC50 values in nM)
sst1 sst2 sst3 sst4 sst5
SS-14 2.3 0.2 1.4 1.8 0.9
Octreotide 1000 0.6 34.5 1000 7
Lanreotide 1000 0.8 107 1000 5.2
Vapreotidea 1000 5.4 31 45 0.7
MK-678a 1000 1.5 27 127 2
BIM-23268 18.4 15.1 61.6 16.3 0.4
BIM-23197 1000 0.2 26.8 1000 9.8
BIM-23244 1000 0.3 133 1000 0.7
SOM-230 9.3 1.0 1.5 100 0.2
Data are derived from Refs. 8, 74, and 191.
a Values represent Ki values in nM (Refs. 8, 187, 188, 191).
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mors, or carcinoid tumors (2, 11), but also for the possibility
to visualize sst-positive tumors using radiolabeled SS-
analogs (see Section II). Knowledge of the sst subtype ex-
pression patterns in human neuroendocrine tumors may be
very important for the development of the concept of sst-
targeted radiotherapy or chemotherapy. As will be discussed
below, sst subtypes differ in their ability to internalize re-
ceptor-bound ligand, which is a crucial step to direct a SS-
analog-linked radioisotope or cytotoxic compound to the
nucleus of the tumor cell.
C. Agonist-induced internalization of sst subtypes
Since the cloning of the five sst subtypes, the involvement
of the individual sst subtypes in the process of receptor-
mediated internalization of SS has been extensively investi-
gated. Although differences have been reported between
human and rat sst subtypes with respect to their dynamics
of agonist-induced internalization, Section I.C is focused pri-
marily on human sst subtypes and briefly summarizes their
reported ability to undergo internalization after exposure to
agonists. The mechanisms involved in receptor-mediated
internalization of sst subtypes are not the focus of this review,
and they have been reviewed elsewhere (8, 9, 42–46). In
general, the mechanism and route of internalization of sst-
agonist complexes follow those described for many other G
protein-coupled receptors (47–50) and involve aggregation
of the hormone receptor complex in specialized areas of the
membrane, followed by internalization of the hormone-
receptor complex via clathrin-coated, as well as uncoated,
pits (47, 51). After internalization and pit formation, fusion
of these vesicles with lysosomes occurs, resulting in hormone
degradation or receptor recycling to the cell surface (Fig. 1;
Refs. 49, 52, and 53).
The sst subtypes differentially internalize SS and SS-
analogs (9). In Chinese hamster ovary (CHO)-K1 cells stably
expressing one of the five human sst subtypes, sst2, sst3, sst4,
and sst5 receptors displayed rapid (within minutes) agonist-
dependent internalization of [125I]LTT SS-28 ligand in a time-
and temperature-dependent manner (54). Maximum inter-
nalization of the radioligand occurred within 60 min. The
sst3- and sst5-expressing cells displayed the highest degree of
internalization (78% and 66%, respectively), followed by sst4
(29%) and sst2 (20%). In contrast, the sst1 subtype displayed
only a very low amount (4%) of internalization. Another
study using COS-7 cells transfected with the human sst1
(hsst1) or hsst2A receptor subtypes (55) recently confirmed
the low internalization rate of the sst1 subtype. These inves-
tigators used confocal microscopy to analyze the fate of in-
ternalized novel fluorescent SS derivatives (43). In cells trans-
fected with sst2A receptors, up to 75% of specifically bound
fluorescent ligand was recovered inside the cells within 60
min after agonist exposure, where it clustered into small
endosome-like particles (55), whereas the capacity of inter-
nalization of SS via the sst5 receptor was intermediate be-
tween sst1 and sst2A receptors (43). These particles increased
in size over time, suggesting that the receptor-ligand com-
plexes followed an endocytotic pathway.
Recent observations by Rocheville et al. (56) demonstrated
that internalization of human sst subtypes can be determined
by functional homo- and heterodimerization of sst subtypes
as well. The hsst1 receptors displayed no internalization of
their selective ligand 125I-SCH288, consistent with their in-
ability to undergo agonist-induced internalization as a
monotransfectant (57). However, when hsst1 receptors were
cotransfected with a c-tail deletion mutant of hsst5, a slight
but significant internalization of 125I-SCH288 at 60 min was
TABLE 2. Expression of sst subtypes in human tumors
Tumor type
SS receptor subtype
sst1 sst2 sst3 sst4 sst5
mRNA Protein mRNA Protein mRNA Protein mRNA Protein mRNA Protein
Pituitary tumor
Somatotroph 44% (25) 96% (28) 44% (25) 5% (22) 86% (22)
Lactotroph 84% (19) 63% (19) 35% (17) 6% (17) 71% (17)
Nonfunctioning 38% (24) 75% (24) 43% (23) 13% (23) 48% (23)
Corticotroph 56% (9) 67% (9) 25% (8) 0% (7) 86% (7)
Neuroendocrine
GEP tumors
Carcinoid 76% (59) 88% (8) 80% (84) 78% (63) 43% (58) 68% (47) 77% (44)
Gastrinoma 79% (28) 100% (5) 93% (28) 100% (8) 36% (28) 61% (23) 93% (28)
Insulinoma 76% (21) 81% (21) 38% (21) 58% (19) 57% (21)
Nonfunctioning
ICT
58% (24) 88% (24) 42% (24) 48% (21) 50% (24)
Renal cell cancer 85% (13) 100% (13) 0% (13) 50% (12)
Breast cancer 33% (103) 52% (33) 99% (103) 48% (33) 38% (101) 48% (33) 23% (97) 18% (51)
Meningioma 46% (24) 100% (24) 33% (24) 50% (12) 71% (14)
Glioma 100% (7) 100% (7) 67% (6) 71% (7) 57% (7)
Neuroblastoma 0% (6) 100% (15) 17% (6)
Colorectal cancer 27% (41) 87% (41) 22% (41) 10% (41) 46% (41)
MTC 29% (14) 79% (14) 36% (14) 0% (14) 64% (14)
Pheochromocytoma 100% (11) 80% (5) 100% (11) 90% (20) 73% (11) 73% (11) 73% (11)
Data on mRNA expression are derived from Refs. 20, 27, 30–34, 69, 70, 72, 192–199 and include studies using RT-PCR, Northern blotting,
and in situ hybridization techniques. Data on protein expression include immunohistochemical studies using sst subtype-specific antibodies
and are derived from Refs. 36–38 and 69. The values represent the percentage of tumors expressing the sst subtype among the tumors screened;
the values between parentheses indicate the total number of tumors of the studies included. GEP, Gastroenteropancreatic; ICT, islet cell tumor;
MTC, medullary thyroid carcinoma.
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observed. Heterodimerization of epitope-tagged sst2A and
sst3 receptors prevents agonist-induced endocytosis of sst3
but not sst2A receptors (58). Apart from changes in function-
ality of individual sst subtypes due to receptor dimerization,
sst receptors may also form heterodimers with other G
protein-coupled receptors, e.g., dopamine and opioid recep-
tors (59, 60). Again, such heterodimers have properties dif-
ferent from the individual receptors. Therefore, the knowl-
edge that homo- and heterodimerization of sst subtypes, and
of sst subtypes with other G protein-coupled receptors, may
influence the capacity of individual sst subtypes to undergo
agonist-induced endocytosis clearly indicates the need to
study internalization of sst subtypes endogenously ex-
pressed in sst-positive cells. Such studies will help to clarify
the apparent discrepancies in internalization of specific sst
subtypes. The above-described ability of sst subtypes to un-
dergo agonist-induced internalization is an important char-
acteristic of these receptors for transporting radiolabeled
SS-analogs into the cell, thereby making sst-targeted radio-
therapy a feasible approach to treat patients with neuroen-
docrine tumors expressing a high density of sst. In Section II,
the preclinical evidence for internalization of radiolabeled
SS-analogs, resulting in accumulation of intracellular radio-
activity, by tumor cells endogenously expressing sst sub-
types, is reviewed.
II. Consequences of sst Internalization for sst-
Targeted Radiotherapy or Chemotherapy of sst-
Positive Tumors
A. Preclinical evidence for internalization of radiolabeled
SS-analogs
Human sst-positive tumors show a high uptake of [111In-
DTPA0]octreotide at sst scintigraphy (13). Analysis of the
uptake of [111In-DTPA0]octreotide by scintigraphy is prefer-
ably performed 24 h after the injection of the radiopharma-
ceutical (13). After 24 h, it is unlikely that the radioactivity in
the tumors reflects cell membrane-bound ligand, but in fact,
more likely, represents internalized radioligand. Internaliza-
tion of [111In-DTPA0]octreotide in vivo is also evidenced by
our observations in rats, in which uptake of radioactivity in
sst-positive organs, such as the pituitary gland and the pan-
creas, after the injection of the radiopharmaceutical, can be
prevented by injection of excess unlabeled octreotide up to
10 min post injection, but not 20 min post injection. At that
time, all radioactivity present in the sst-positive tissues prob-
ably reflects internalized radioligand (61). Direct evidence
for internalization and subsequent subcellular distribution of
radioisotopes delivered to the tumor cells using radiolabeled
SS-analogs is presented from several ex vivo and in vitro
autoradiographic studies. After incubation of human HT-29
colon carcinoma cells with the 3H-labeled SS-analog TT-232,
radioactivity was observed at the cell surface and cytoplas-
mic membranes, as well as the nucleus (62). Comparable
observations were made in primary cultures of human car-
cinoid and gastrinoma cells incubated in vitro with [111In-
DTPA0]octreotide (63). The primary cultures specifically
bound and internalized this radiopharmaceutical. About
50% of the internalized radioactivity was released by the cells
within 6 h, whereas the remaining radioactivity was trapped
within the cells up to 42 h. Electron microscopic autoradiog-
raphy demonstrated the presence of the internalized 111In in
the cytoplasm and the nucleus. The same processes also
apply to the in vivo situation. From seven patients with ma-
lignant midgut carcinoid tumors, who received an iv injec-
tion of 200 MBq [111In-DTPA0]octreotide 2 d before abdom-
inal surgery, tumor tissue was obtained and analyzed for the
subcellular distribution of radioactivity using ultrastructural
autoradiography (64). In all patients, the carcinoid tumor
could be visualized by preoperative scintigraphy. By ex vivo
autoradiography, silver grains were found at the plasma
membrane, in the cytoplasmic areas among secretory gran-
ules and vesicular compartments, but also in the perinuclear
area. This localization of 111In in close proximity to the cell
nucleus is especially important for this short range Auger
electron-emitting radioisotope to exert its cytotoxic effect
FIG. 1. Schematic representation of in-
tracellular routing of G protein-coupled
receptors (GPCRs) after agonist activa-
tion. After agonist activation, GPCRs
are phosphorylated (involving protein
kinase A, protein kinase C, and GPCR
kinases) and internalized, probably via
the formation of clathrin-coated pits
(involving -arrestins). The internal-
ized receptors are then directed to endo-
somes in which they are dephosphory-
lated. Subsequently, the receptors are
recycled back to the plasma membrane
as functional (resensitized) receptors.
GPCR down-regulation results from ly-
sozomal degradation of intracellular re-
ceptors, decreased mRNA and receptor
protein synthesis, as well as increased
degradation via mobilization of mem-
brane receptors directly to the lysoso-
mal compartment. L, Ligand; PP, phos-
phate group. [Adapted from Ref. 49.]
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in the form of DNA-double strand damage (see Section II.B
and Ref. 64).
1. Factors determining the uptake and cellular retention of ra-
dioactivity delivered via sst-mediated internalization. [111In-
DTPA0]octreotide is a sst2-preferring ligand, which suggests
an important role of sst2 in determining the accumulation of
radioactivity in tumor cells after internalization of the radio-
ligand-receptor complex. Radiolabeled octapeptide SS-
analogs are internalized in a high amount by sst-positive
mouse and human tumor cells (63, 65–67). Evidence for a role
of the sst2 subtype in mediating the uptake of the radiophar-
maceutical [111In-DTPA0]octreotide by sst-positive tumors is
presented from studies showing that sst2-expressing cells
internalize SS (54), as well as octreotide (68). Moreover, sst2
receptor expression correlates well with the relative uptake
values of [111In-DTPA0]octreotide in patients with carcinoid
tumor (69), as well as patients with neuroblastoma (70). On
the other hand, on the basis of the high SS-internalization
rates of the sst3 and sst5 subtypes, as reported by Hukovic et
al. (54), it cannot be excluded that sst3 and sst5 might play a
role as well. In fact, a role of the sst3 subtype in the uptake
of [111In-DTPA0]octreotide is evident from a recent study by
our group demonstrating a significant uptake in a patient
with a thymoma. In vitro studies revealed the absence of
sst2A, sst2B, and sst5 receptors and a predominant expression
of sst3 receptors in the tumor tissue (71). The hypothesis that
sst subtypes other than sst2 receptors may be involved in the
uptake of [111In-DTPA0]octreotide in vivo is further under-
lined by the observation that sst scintigraphy visualized tu-
mor sites in three patients with thyroid tumors (one MTC,
one Hu¨rthle cell adenoma, and one Hu¨rthle cell carcinoma),
which lacked sst2 mRNA expression but expressed the other
four sst subtypes (72), as well as in a patient with a pro-
opiomelanocortin and CRH-expressing MTC (sst2 negative;
sst1-, sst3-, and sst5-mRNA positive; Ref. 73).
As discussed in Section I.A (Table 1), octapeptide SS-
analogs such as octreotide bind with high affinity to sst2 and
with lower affinity to sst3 and sst5 (74, 75). Therefore, both the
affinity of the radioligand for the receptor and the efficiency
of internalization of the radioligand-receptor complex can be
important factors in determining the uptake of radioactivity
in sst scintigraphy of sst-positive tumors. Moreover, the dif-
ferential expression of sst subtypes in tumors (Table 2), as
well as the level of sst subtype expression, may play a role.
Until now, data on the differential internalization of SS by sst
subtypes were derived from studies using cell lines trans-
fected to overexpress the individual sst subtypes (Section I.C).
Data on the internalization of SS ligands by (tumor) cells
endogenously expressing sst subtypes are needed to evalu-
ate the real significance of these findings for human sst-
positive tumors. Because most human tumors express mul-
tiple sst subtypes, the development of novel sst subtype-
selective agonists and antagonists will also be of help to
unravel this question. Receptor-mediated endocytosis of SS-
analogs is especially important when radiotherapy of human
sst-positive tumors using radiolabeled SS-analogs is consid-
ered. Internalization of radioligand will result in a prolonged
cellular retention of radioactivity, thus resulting in a pro-
longed exposure of the tumor cell to radiation. Human neu-
roendocrine tumor cells internalize the radioligand [111In-
DTPA0]octreotide. However, this radiopharmaceutical
may not be the most suitable compound to carry out radio-
therapy because the Auger electrons emitter 111In has a low
tissue penetration. In addition, a stable coupling of - or
-emitting isotopes to [DTPA0]octreotide could not be
achieved, which initiated the development of a novel com-
pound, [DOTA0,Tyr3]octreotide, in which the diethylene-
triamine pentaacetic acid (DTPA) molecule is replaced by
another chelator, tetraazacyclododecane tetraacetic acid
(DOTA), allowing a stable binding with the -emitter
yttrium-90 (90Y) (76). Recently, we demonstrated that iodin-
ated [DOTA0,Tyr3]octreotide is internalized in a high
amount by mouse AtT20 pituitary tumor cells, as well as by
human insulinoma cells (77). Internalization of iodinated
[DOTA0,Tyr3]octreotide was approximately 5-fold higher,
compared with the iodinated DTPA-coupled parent mole-
cule, [DTPA0,Tyr3]octreotide. Therefore, coupling of the oc-
treotide molecule to these chelating groups does not prevent
internalization of the hybrid molecules. The high internal-
ization rate of [DOTA0,125I-Tyr3]octreotide in vitro was also
evident from the very high uptake of this radioligand in vivo
in sst-positive organs in rats. De Jong et al. (78) recently
showed that the amount of [90Y-DOTA0,Tyr3]octreotide in-
ternalized by sst-positive pancreatic tumor cells was signif-
icantly higher than that of [111In-DOTA0,Tyr3]octreotide and
[111In-DTPA0]octreotide (1.8- and 3.5-fold, respectively).
Moreover, in eight patients with sst-positive tumors, a higher
uptake value of [111In-DOTA0,Tyr3]octreotide compared
with that of [111In-DTPA0]octreotide was found in normal
sst-positive organs like the spleen and pituitary gland, as
well as in most tumors (79). If [90Y-DOTA0,Tyr3]octreotide
has the same characteristics of uptake in sst-positive cells, it
may be a suitable radiopharmaceutical for sst-targeted
radiotherapy.
After internalization of the receptor-radioligand complex,
an important process is the retention of radioactivity within
the tumor cells. For iodinated SS ligands, it seems clear that
a significant proportion of radioactivity is rapidly excreted.
This may be due in part to the excretion of radioligand
degradation products, although recycling of the receptor-
ligand complex may play a role as well. Recycling of SS
receptors after being internalized has been demonstrated for
sst2 (80) and sst3 (44, 81) receptors. Koenig et al. (80) also
showed that biologically active SS agonists were excreted
after being internalized by sst2-expressing CHO cells. There-
fore, trapping of radioisotopes into tumor cells may be an
additional important mechanism determining the amount of
uptake of radioligand that is used for sst scintigraphy and
targeted radiotherapy. In this respect, Duncan et al. (82)
previously demonstrated that [111In-DTPA0]octreotide is
delivered in vivo to pancreatic tumor cell lysosomes and
proposed that lysosomes play a critical role in the cellular
physiology of radiolabeled SS-analogs. The internalized
[111In-DTPA0]octreotide was shown to be metabolized to
111In-DTPA-d-Phe in vivo (83, 84). Accumulation of radio-
activity in nuclear-lysosomal density gradient fractions
was also found in neuroblastoma cells exposed in vitro
to the radioligand (85). For the radioligand [90Y-DOTA0,
Tyr3]octreotide, it remains to be determined whether similar
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processes occur. Finally, uptake of radiolabeled [DTPA0]-
octreotide in rats and humans (61, 86), as well as that of
[DOTA0,Tyr3]octreotide in rats (87), demonstrated a bell-
shaped curve, dependent upon the amount of injected pep-
tide. Studies to determine the optimal peptide mass for up-
take of radioactivity in human tumors after the injection of
radiolabeled SS-analogs are ongoing (87).
As shown in Table 1, different octapeptide SS-analogs such
as octreotide, lanreotide, and vapreotide (RC-160) interact
with the same subclass of sst subtypes (sst2, sst3, and sst5).
Nevertheless, slightly different affinities for the different sst
subtypes have been found (Table 1). However, in vivo studies
in rats (88) and humans (89) comparing uptake values of
[111In-DTPA0]RC-160 and [111In-DTPA0]octreotide showed
that [111In-DTPA0]RC-160 has no additional value for scin-
tigraphy. In fact, the use of [111In-DTPA0]RC-160 is associ-
ated with higher background activity (89). Another recently
developed radiopharmaceutical, 111In- or 90Y-labeled DOTA-
lanreotide, bound with high affinity to hsst2–hsst5 and with
low affinity to hsst1 expressed in COS-7 cells, suggesting that
this radiolabeled peptide may also be useful for sst scintig-
raphy or radiotherapy (90). Apart from differences in the
affinity profiles of unlabeled SS-analogs due to structural
differences, radiolabeling of such analogs has major effects
on binding affinity for the different human sst subtypes as
well (91). Yttrium labeling of [DOTA-Tyr3]octreotide,
DOTA-lanreotide, and DOTA-RC-160 significantly in-
creases binding affinities for sst3 and sst5 receptors. Such
differences, in combination with the high internalization
rates of sst3 and sst5 receptors (54), could very well account
for the higher cellular uptake values in vivo and in vitro
of [90Y-DOTA0,Tyr3]octreotide, compared with [111In-
DTPA0,Tyr3]octreotide and [111In-DTPA0]octreotide (77–
79). Therefore, several characteristics of SS-analogs devel-
oped for sst scintigraphy and radiotherapy, such as small
structural modifications, chelator substitution, or type of
radioisotope, considerably affect binding affinity (91).
Preclinical studies have shown that down-regulation of SS
receptors may occur during agonist exposure. On the other
hand, agonist-induced up-regulation of sst expression has
been demonstrated as well (see Section III.D.1). Agonist-
induced regulation of tumoral sst expression may theoreti-
cally influence the results of sst scintigraphy and the efficacy
of targeted radiotherapy. The few available clinical data on
this issue add to the equivocal data regarding up-regulation
and/or down-regulation of SS receptors upon exposure to SS
or SS-analog treatment. In five patients with metastatic MTC
who were studied before and after 3 months of therapy with
a high dose of octreotide, tumor/background ratios deter-
mined by sst scintigraphy were reduced in 14 of 18 metas-
tases, suggestive of a down-regulation of SS receptors by
octreotide therapy (92). Moreover, reduced orbital uptake of
octreoscan was observed in 10 patients with thyroid eye
disease after 3 months of treatment with lanreotide or oct-
reotide (93). On the other hand, in patients with a soma-
tostatinoma, the tumors can be visualized by sst scintigraphy
(94, 95), suggesting that a complete sst down-regulation does
not occur in this type of tumor. Finally, Dorr et al. (96) re-
ported decreased uptake of octreoscan in the liver, spleen,
and kidney during continuous octreotide therapy, whereas
tumor uptake values were increased simultaneously in five
patients with metastatic carcinoid disease and decreased in
one patient with advanced MTC. In conclusion, homologous
down-regulation of sst expression may be (tumor) cell type
specific, as was already evident from experimental studies
(see Section III.D.1).
In conclusion, it is well established now that radiolabeled
SS-analogs, including those that are used for sst scintigraphy
and sst-targeted radiotherapy, can be internalized by sst-
positive tumor cells. Several mechanisms may determine the
amount of uptake of radiolabeled SS-analogs. These include
stability of the radioligand, the expression levels of individ-
ual sst subtypes, the affinity of the radioligand for the sst
(subtype), the efficiency of receptor internalization and re-
cycling that may be different between sst subtypes, the final
trapping of the radioisotopes within the tumor cells, as well
as the mass of the injected peptide (summarized in Table 3).
B. SS receptor-targeted radiotherapy
1. Preclinical evidence. Several preclinical studies have dem-
onstrated tumor growth-inhibitory effects after treatment
with radiolabeled SS-analogs. In athymic mice bearing sst-
positive PC-3 prostatic adenocarcinoma, Zamora et al. (97)
showed that intratumoral injections with seven 200-Ci
doses of the -emitting 188Re-RC-160 SS-analog reduced tu-
mor size by 90%. Additionally, a significantly higher pro-
portion of survivors was observed in the group treated with
188Re-RC-160. In this study, treatments were initiated 19 d
after inoculation of PC-3 tumor cells when the animals car-
ried solid tumors (500–1000 mm3). In addition, three serial
treatments with regionally injected 200 Ci 188Re-RC-160
decreased tumor burdens in experimental models of H-69
human small cell lung cancer cells or ZR-75-1 mammary
adenocarcinoma cells xenografted into the pleural cavity of
athymic mice (98). Tumor ablation was observed in up to
60% of the animals bearing H69 tumors and in 40% of the
animals bearing ZR-75-1 tumors (98). In another study in
nude mice bearing solid sst-positive AR42J pancreatic tu-
mors, a single treatment with 500 Ci of another SS-
analog, radiolabeled with the -emitting isotope 90Y, e.g.,
[90Y]SDZ413, decreased tumor mass by 75% 8 d after in-
jection and prolonged survival, although tumor regrowth
was observed after 2 wk of treatment (99). More recently,
a significant radiotherapeutic effect of the 90Y-labeled SS-
analog [90Y-DOTA-d-Phe1,Tyr3]octreotide was demon-
strated by the same group of investigators in rats bearing
solid sst-positive pancreatic CA 20948 tumors (76). A sin-
gle iv administration of 10 mCi/kg [90Y-DOTA-d-
Phe1,Tyr3]octreotide resulted in a complete remission of
TABLE 3. Factors important in determining the amount of tumoral
uptake of radiolabeled SS-analogs
1. Stability of the radioligand
2. Density of SS receptors expressed on tumors
3. Type of SS receptors expressed by tumors
4. Affinity of radioligand for sst subtype(s) expressed by tumors
5. Efficiency of receptor subtype-mediated internalization of
radioligand
6. Trapping of radioisotopes within the tumor cell
7. Mass of the injected radiopharmaceutical
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the tumors in five of seven (71%) tumor-bearing rats. In
this study, no tumor regrowth had occurred even 8 months
post injection. This pancreatic CA 20948 tumor expressed
a high level of sst2 mRNA and a low level of sst5 mRNA,
suggesting that the radiotherapeutic effect of [90Y-DOTA-
d-Phe1,Tyr3]octreotide was mediated via targeting the
sst2 receptor subtype. [
90Y-DOTA-d-Phe1,Tyr3]octreotide
is the radiopharmaceutical that is currently being tested in
ongoing clinical phase I and II trials (see Section II.B.2).
Whereas solid experimental tumor models were used in
the above studies, Slooter et al. (100) recently studied the
radiotherapeutic effect of [111In-DTPA0]octreotide in a rat
model of hepatic metastasis of different tumor cell lines. In
this study, the development of hepatic metastases was de-
termined 21 d after injection of sst-positive or sst-negative
tumor cells into the vena porta in rats. Tumor-bearing rats
were treated twice (d 1 and d 8) with 370 MBq of [111In-
DTPA0]octreotide. These investigators demonstrated a sig-
nificant reduction in the number of liver metastases by this
treatment regimen in the sst-positive tumor model, but not
in the sst-negative tumors. This suggests that the presence of
sst on the tumor cells is required for effectiveness of treat-
ment with radiolabeled SS-analogs. This was further con-
firmed by their observation that the radiotherapeutic effect
of [111In-DTPA0]octreotide could be blocked by coinjection
with a sst-saturating dose of unlabeled octreotide (100). As
indicated above, it should be mentioned that 111In is not a
-emitting radioisotope, but emits -rays, internal conver-
sion, and Auger electrons. Internal conversion and Auger
electrons have a medium- to short-range tissue penetration
(200–500 m and 0.02–10 m, respectively), and it is sug-
gested that these radiochemical properties of 111In cause the
radiotherapeutic effect of [111In-DTPA0]octreotide. Because
in this study the tumor load was relatively small, studies of
the radiotherapeutic effect of [111In-DTPA0]octreotide in ex-
perimental models of more advanced stages of tumor de-
velopment are required (100).
Recently, a novel 177lutetium (177Lu, a low-energy -
particle and -emitter) radiolabeled SS-analog, i.e., [177Lu-
DOTA,Tyr3]octreotate, has been proven to be a very prom-
ising radiopharmaceutical. Preclinical studies in rats bearing
CA 20948 pancreatic tumors demonstrated even a 100% cure
of small (1 cm2) tumors after two repeated doses of 277.5 MBq
or one single dose of 555 MBq of [177Lu-DOTA,Tyr3]octreotate
(101). In rats with larger tumors (1 cm2; range, 1.4–10 cm2),
cure rates between 40% and 50% were observed (102). In rats
bearing AR42J pancreatic tumors, which had a more favor-
able uptake compared with the CA 20948 model, treatment
with 555 MBq of [177Lu-DOTA,Tyr3]octreotate resulted in an
almost 100% cure, irrespective of the tumor size (102). On the
basis of the distinct properties of the two radionuclides and
the results of preclinical studies, this group of investigators
proposed the use of a combination of 90Y- and 177Lu-labeled
SS-analogs, because 90Y is particularly effective in large tu-
mors and 177Lu seems most effective in small tumors (102).
Preliminary results in a rat model with tumors of more than
one size indeed showed longer survival rates with the com-
bined treatment, compared with treatment with the 90Y- or
177Lu-labeled SS-analogs alone (103).
It is well known that tumor cells display various degrees
of sensitivity to radiation. Adenovirus-based transfer of
wild-type (wt) p53 tumor suppressor gene sensitizes ovarian
tumor cells to radiation-induced apoptosis (104). In addition,
overexpression of the tumor suppressor gene Bax can sen-
sitize tumor cells to radiation, as well as to chemotherapy-
induced apoptosis (105, 106). Of particular importance in this
respect are recent studies demonstrating that octreotide in-
duces wt p53 and Bax in MCF-7 human breast cancer cells
(107). SS-mediated induction of wt p53 and apoptosis is
selectively induced via sst3 (108), in contrast to p53-inde-
pendent, retinoblastoma protein-mediated signaling of cell
cycle arrest (109, 110). The majority of human sst-positive
tumors express sst3 (Section I). It cannot be excluded, there-
fore, that the therapeutic potential of internalized radionu-
clide may be limited by the lack of expression of a functional
p53 or sst3. On the basis of their observations, Sharma and
Srikant (107) suggested that - or -emitting octreotide-
tagged radionuclides should elicit maximal cytotoxic re-
sponse due not only to radiation-induced damage after in-
ternalization, but also to the triggering of apoptosis via the
induction of wt p53 and Bax by receptor-mediated signaling.
Moreover, on the basis of these data, it is predicted that
treatment with SS-analogs alone or in combination with ra-
diation and/or chemotherapy will be most effective in treat-
ing wt p53- and sst-expressing tumors not only of the breast
but also of other organs (107).
Taking the preclinical studies together, it can be concluded
that radiotherapy using radiolabeled SS-analogs is effective
in experimental sst-positive tumor models and that sst-
targeted radionuclide therapy may be a feasible approach to
treat patients with advanced, metastatic sst-positive neuro-
endocrine tumors.
2. Clinical evidence. In 1989, the technique of sst scintigraphy
to visualize sst-positive tumors in man was developed using
the radiolabeled SS-analog [123I-Tyr3]octreotide (12). Because
the use of this radiopharmaceutical had a number of draw-
backs (i.e., expensive, lack of availability, short physical half-
life, and predominant hepatic clearance resulting in accu-
mulation of radioactivity in liver, gall bladder, bile ducts, and
gastrointestinal tract; Ref. 2), novel SS-analogs were devel-
oped to circumvent these disadvantages. As described
above, the most widely used SS-analog for sst scintigraphy
is a DTPA-coupled octreotide. The radioisotope 111In binds
with very high affinity to the DTPA molecule, and [111In-
DTPA0]octreotide has proved to be a highly suitable radio-
pharmaceutical for the detection of sst-positive tumors
by -camera scintigraphy (13). Apart from its use in sst
scintigraphy, [111In-DTPA0]octreotide has been used for
radiotherapeutic application as well (111, 112). Although
no controlled trials have been performed with [111In-
DTPA0]octreotide, preliminary reports demonstrate a cer-
tain degree of efficacy of this radiopharmaceutical in the
treatment of selected, high sst-expressing metastasized
neuroendocrine tumors. Krenning et al. (111) reported
treatment with [111In-DTPA0]octreotide, up to maximal
cumulative patient doses of 74 GBq in a phase I trial of 30
end-stage patients with neuroendocrine tumors that all
demonstrated recent progression. They reported promis-
ing beneficial effects on clinical symptoms, hormone pro-
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duction, and tumor size. In 21 patients who received a
cumulative dose of more than 20 GBq, 8 patients showed
stabilization of disease, and 6 others demonstrated a re-
duction in tumor size. In a few patients, a transient decline
in platelet counts and lymphocyte subsets occurred (111).
More recently, this group of investigators reported on 40
evaluable patients treated with doses of at least 20 GBq up
to 160 GBq. In 21 patients, therapeutic effects were ob-
served: partial remission in 1, minor remissions in 6, and
stabilization of previously progressive disease in 14 pa-
tients. On the basis of the observation that three of six
patients, who received more than 100 GBq of [111In-
DTPA0]octreotide, developed myelodysplastic syndrome
or leukemia, 100 GBq was considered to be the maximal
tolerable dose (113). In another study, 14 patients with
sst-positive malignancies of different types were treated
with two monthly doses of 180-mCi iv injections of [111In-
DTPA0]octreotide. Clinical benefit occurred in 6 of 10
patients with gastroenteropancreatic tumors, objective partial
radiographic responses occurred in 2 of 14 patients, and sig-
nificant tumor necrosis occurred in 6 of 10 patients. Possible
treatment-related toxicity included myelosuppression (114). In
a patient with a midgut carcinoid tumor, treatment with thera-
peutic doses of [111In-DTPA0]octreotide induced symptomatic
relief, including a slight reduction in levels of the main tumor
marker, urinary 5-hydroxyindolacetic acid (5-HIAA). Again, a
slight reduction in leukocyte counts was observed as adverse
reaction (112). These data suggest that radiotherapy with high
doses of [111In-DTPA0]octreotide might be useful as a thera-
peutic agent in patients with sst-positive malignancies. The
therapeutic effect of [111In-DTPA0]octreotide seems due to the
emission of Auger and conversion electrons having a low tissue
penetration (see Section II.B.1 and Ref. 111). 111In may therefore
not be the most optimal radionuclide for sst-targeted radionu-
clide therapy. For this, novel DOTA-chelated SS-analogs have
been synthesized, which allow a fixed binding of -emitting
radionuclides, such as 90Y. Recently, clinical trials using [90Y-
DOTA0,Tyr3]octreotide as well as another DOTA-coupled
SS-analog, e.g., [90Y-DOTA]lanreotide, have been initiated. Pre-
liminary results with [90Y-DOTA0,Tyr3]octreotide demon-
strated promising effects in patients with different types of
sst-positive neuroendocrine tumors (115). Multiple treatments
with [90Y-DOTA0,Tyr3]octreotide resulted in stable disease in
three of six patients and partial remission in the remaining
patients. In two of four patients who received a single treatment
with [90Y-DOTA0,Tyr3]octreotide, tumor glucose uptake
was reduced, whereas the other two showed clinical im-
provement and stable disease. In a larger group of patients
with advanced sst-positive tumors of different origin, a
[90Y-DOTA0,Tyr3]octreotide intrapatient dose escalation
study has been performed. In this study, 29 patients received 4
or more single doses of [90Y-DOTA0,Tyr3]octreotide with as-
cending activity at intervals of approximately 6 wk. Preliminary
results showed disease stabilization in 20 of the 29 patients,
partial remission in 2, a reduction in tumor mass of less than
50% in 4, and progression of tumor growth in 3 patients (116).
However, a significant proportion of the patients (5 of 29, or
17%) developed renal and/or hematological toxicity. Studies
directed to reduce renal toxicity, i.e., amino acid infusions,
are ongoing (116). Paganelli et al. (117, 118) reported favorable
preliminary results regarding tumor growth using [90Y-
DOTA0,Tyr3]octreotide as well. A recent phase II study, in-
cluding 41 patients with neuroendocrine, gastroenteropancre-
atic, and bronchial tumors and 82% of patients with therapy-
resistant and progressive disease, showed an overall response
rate of 24%. Side effects included grade III (NCIGC) pancyto-
penia in 5% and vomiting shortly after injection in 23%. No
grade III-IV renal toxicity was observed (119). To evaluate the
clinical benefit and objective response rate of high-dose [90Y-
DOTA0,Tyr3]octreotide treatment (4 equal iv injections totaling
7.4 GBq/m2 with renal protection), a phase II study in 39 pa-
tients with progressive neuroendocrine, gastropancreatic, and
bronchial tumors was performed (120). The results showed an
overall objective response rate of 23% (World Health Organi-
zation criteria: complete remission in 5%, partial remission in
18%, stable disease in 69%, progressive disease in 8%). In the
patients with endocrine pancreatic tumors, objective response
rate was 38% (13 patients). The overall clinical benefit in this
study was 63%. Side effects were grade III or IV lymphocyto-
penia (23%), grade III anemia (3%), and grade II renal insuffi-
ciency (3%). Finally, in a patient with metastatic gastrinoma
treated with [90Y-DOTA]lanreotide, a 25% reduction in liver
metastases as indicated by computed tomography was ob-
served (121). In conclusion, the results of sst-targeted radio-
therapy with [90Y-DOTA0,Tyr3]octreotide are most encourag-
ing and extend the therapeutic options in the treatment of
patients with sst-positive neuroendocrine tumors.
Very recently, Kwekkeboom et al. (122) introduced a
novel DOTA-tagged SS-analog, e.g., [DOTA0,Tyr3]octreotate
(in which the C-terminal threoninol is replaced with thre-
onine), radiolabeled with the - and -emitting 177Lu,
as a potential promising radiotherapeutical with a 3- to
4-fold higher tumoral uptake of radioactivity compared
with [111In-DTPA0]octreotide. [DOTA0,Tyr3]octreotate has
a 9-fold increased affinity for sst2, compared with
[DOTA0,Tyr3]octreotide, and a 6- to 7-fold increase in
affinity for their yttrium-loaded counterparts (91). Pre-
liminary promising results using this radiopharmaceutical
have been reported (102, 103).
C. SS receptor-targeted chemotherapy: preclinical evidence
The wide spectrum of adverse reactions when treating
patients with advanced, metastatic tumors with chemother-
apeutic agents are caused by the severe toxicity of these
agents to normal cells. Like peptide receptor-targeted radio-
therapy, targeted chemotherapy to deliver the chemothera-
peutic compounds selectively to tumor cells might be a
promising approach as well. Schally and Nagy (123) pio-
neered this concept with the development of cytotoxic an-
alogs of LHRH, cytotoxic bombesin analogs, and cytotoxic
SS-analogs, to treat LHRH receptor-, bombesin receptor-,
and sst-positive tumors, respectively. This group of inves-
tigators provided preclinical evidence for the effectiveness of
cytotoxic LHRH analogs in experimental models of human
ovarian, mammary, or prostatic cancer (123), as well as for
the effectiveness of cytotoxic bombesin analogs in the treat-
ment of experimental models of bombesin receptor-positive
small cell lung carcinoma, colorectal, gastric, pancreatic,
mammary, and prostatic cancers (123). Schally and co-work-
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ers (124, 125) synthesized two different cytotoxic SS-analogs,
code-named AN-51, consisting of methotrexate linked to the
N terminal of the octapeptide SS-analog RC-121 and AN-238,
which is the RC-121 analog linked to a highly potent deriv-
ative of doxorubicin, e.g., 2-pyrrolinodoxorubicin. Both the
AN-51 and AN-238 compounds had intermediate binding
affinities to sst-positive tissues in vitro, in comparison with
the RC-121 compound alone, suggesting that coupling of the
chemotherapeutic compound to the SS-analog slightly re-
duced their binding properties (124, 125). The binding af-
finity of the AN-238 compound for rat pituitary membrane
SS receptors was 23.8 nm, which is comparable to the binding
affinities of several DTPA- and DOTA-coupled SS-analogs to
hsst2 receptors (91). In preclinical studies, it was demon-
strated that both the AN-51 and AN-238 compounds inhib-
ited tumor growth in experimental tumor models. In nude
mice transplanted with the human Mia PaCa-2 pancreatic
tumor, AN-51 significantly inhibited tumor growth, whereas
the chemotherapeutic compound alone, methotrexate, or
RC-121 alone had no significant inhibitory effect (124), and
with methotrexate alone displaying a much higher toxicity
compared with AN-51. Thereafter, this group tested the cy-
totoxic properties of the AN-238 compound, which dis-
played a very high toxicity in sst-positive cells in vitro. Potent
tumor growth inhibitory properties of AN-238 were ob-
served in many experimental mouse and rat models of hu-
man breast cancer, prostate cancer, ovarian cancer, small cell
lung cancer, pancreatic cancer, renal cell cancer, as well as
glioblastoma (126–133). Again, a much higher toxicity and
lower or absent effectiveness on tumor growth was observed
in animals treated with the cytotoxic radical alone. In these
animal studies, the major side effect of treatment with cy-
totoxic SS-analogs was a transient fall in white blood cell
counts. In conclusion, sst-targeted chemotherapy is effective
in preclinical tumor models and seems a highly promising
approach as well to treat sst-positive tumors. The sst-targeted
chemotherapy may result in a chemotherapeutic approach
using lower dosages of the chemotherapeutic compound and
thus lower toxicity. Until now, however, no clinical trials
have been reported using targeted LHRH, bombesin, or SS-
analogs. In addition, evidence will have to be provided that
cytotoxic SS-analogs can also be internalized by sst-positive
tumor cells. As for the concept of sst-targeted radiotherapy,
the efficacy of sst-targeted chemotherapy will be determined
by the amount of uptake of the cytotoxic radicals by the
tumors. Moreover, the effect of cytotoxic SS-analog treatment
on the function of normal sst-expressing cells is to be
determined.
III. Tachyphylaxis and Resistance to SS
A. Introduction
Concomitant with the widespread distribution of sst
throughout central and peripheral tissues, the acute admin-
istration of SS or its analogs induces a large number of mainly
inhibitory effects (8, 9). Nevertheless, these initially potent
responses diminish with continued exposure (9, 11). The
different mechanisms that are potentially involved in this
adaptation or tachyphylaxis to continuous exposure to SS or
SS-analogs may be associated with processes such as receptor
phosphorylation, G protein uncoupling, receptor internal-
ization, and degradation. This has been reviewed extensively
(8, 9). Different from these physiological responses to con-
tinued SS exposure is the response of neuroendocrine tumor
cells. Patients with certain types of sst-positive tumors (e.g.,
GH-secreting pituitary adenomas, islet cell tumors, and car-
cinoids) can be treated for many months to years with the
current clinically available SS-analogs. The long-term control
of hormonal hypersecretion and/or tumor growth by treat-
ment with SS-analogs may vary considerably, however,
among patients. Section III focuses particularly on tachyphy-
laxis and resistance to treatment with the different available
formulations of SS-analogs, as well as the potential mecha-
nisms involved herein. Although the direct fundamental ev-
idence for the clinical observations of tachyphylaxis is rela-
tively weak, several potential mechanisms determining
cellular responsiveness to SS are discussed.
B. Tachyphylaxis of pathological hormone secretion
1. Pituitary adenomas. Whereas normal hormone secretion
shows tachyphylaxis after continuous receptor activation
within hours to days (9), pathological hormone secretion by
sst-positive tumor cells can be inhibited during significantly
prolonged periods. In about half of the patients with GH-
secreting pituitary adenomas, serum GH and IGF-I levels are
normalized by octreotide treatment (134). Escape from SS-
analog therapy has not been observed in this type of patient,
even after many years of continuous treatment (135). Figure
2A shows a typical example of the persistent suppression of
serum IGF-I levels in an acromegalic patient during a period
of 8 yr of treatment with three times daily injections of 50–100
g octreotide. The persistently lowered IGF-I levels seem not
to be caused by radiotherapeutic effects because drug with-
drawal after 5 yr of treatment resulted in an instant rise in
IGF-I levels and immediate recurrence of signs and symp-
toms. Moreover, although no desensitization to continuous
sc treatment with octreotide is observed, acromegalic pa-
tients treated with long-acting formulations of SS-analogs,
i.e., long-acting repeatable octreotide administration (Refs.
135a–135c) or slow-release lanreotide (136) did not show any
signs of tachyphylaxis to treatment periods up to 3 yr as well.
To our knowledge, only one rare case of acromegaly showing
desensitization to octreotide has been described so far (137).
Partial tachyphylaxis to SS-analogs was reported in a patient
with acromegaly. In this patient, previously treated with 90Y
implant, external radiotherapy, and three daily sc injections
with octreotide, GH levels progressively rose after switching
to lanreotide and depot octreotide (Sandostatin LAR, No-
vartis Pharmaceuticals Corp., Basel, Switzerland). Interest-
ingly, there were no signs of tumor growth or alterations in
sst status as determined by [111In-DTPA0]octreotide scintig-
raphy (138). Octreotide withdrawal for 24 h in this patient
resulted in a 64% increased sensitivity in terms of inhibition
of GH levels by recommencing octreotide treatment, sug-
gesting that changes in receptor function or on the receptor
signal transduction cascade play a role, rather than changes
in receptor expression (138).
The majority of TSH-secreting and clinically nonfunction-
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ing pituitary adenomas also express sst (139, 140). Octreotide
treatment of patients with TSH-secreting pituitary adenomas
results in a lowering of TSH levels and normalization of T4
levels in 73% of the patients. In contrast to patients with
GH-secreting pituitary adenomas, in this series of 52 patients
an escape from therapy was observed in 5 patients (10%).
This loss of sensitivity to the inhibitory effect of octreotide on
TSH levels was observed in two patients receiving short-term
therapy and in three patients receiving long-term therapy
(139). Overall, Beck-Peccoz et al. (141) reported tachyphylaxis
in 22% of the patients with a response to increasing octreotide
doses, whereas subsequent escape from the inhibitory effects
was observed in 10% of the cases. The role of SS-analogs in
the treatment of patients with clinically nonfunctioning pi-
tuitary adenomas is less well established, whereas octreotide
seems not of benefit in the treatment of patients with ACTH-
secreting pituitary adenomas or prolactinomas (135). This
may be due to either the absence of sst on the tumor cells or
the absence of expression of particular sst subtypes (135).
2. Islet cell tumors and carcinoids. In striking contrast to the
absence of the occurrence of tachyphylaxis of inhibition of
hormone secretion by octreotide in patients with GH-secret-
ing pituitary adenomas are the observations in patients with
islet-cell tumors and carcinoids. In the majority of patients
with metastatic carcinoids, VIPomas, gastrinomas, insulino-
mas, and glucagonomas, treatment with octreotide induces
a rapid improvement of clinical symptomatology, such as
diarrhea, dehydration, flushing attacks, hypokalemia, peptic
ulceration, hypoglycemic attacks, and necrotic skin lesions
(142–145). On the other hand, the majority of the patients
show desensitization of the inhibition of the secretion of
tumor-related hormones by octreotide within weeks to
months. This effect may be initially reversed by increasing
the dosage of octreotide, but eventually the drug becomes
ineffective in all patients (11). In a series of 57 patients with
the carcinoid syndrome, 23 patients escaped from octreotide
therapy after periods ranging from 1 wk to 12.5 months
(median, 4 months), whereas the other responding patients
could be controlled for periods extending to 2.5 yr. The
estimated mean duration of response to octreotide therapy in
the whole group of responding patients was approximately
1 yr (146). Figure 2B shows a typical example of tachyphy-
laxis of the inhibitory effect of octreotide (100 g three times
per day) on urinary 5-HIAA levels in a patient with a met-
astatic carcinoid tumor. An escape from octreotide treatment
was seen after 3 months of therapy. Increasing the dose of
FIG. 2. Absence of tachyphylaxis to octreotide therapy in a patient with a GH-secreting pituitary adenoma (A) and desensitization in a patient
with metastatic carcinoid tumor (B). A, Effect of octreotide therapy on serum IGF-I level in a patient with a GH-secreting pituitary adenoma.
A 77-yr-old man transsphenoidally operated (TSS) for a GH-secreting macroadenoma that had resulted in active acromegaly. Two months after
incomplete surgery of the tumor, external radiotherapy (RT) was applied. Successively, octreotide therapy was started 6 months after surgery
at a dose of 100 g three times daily. This therapy had resulted in a prolonged suppression of serum IGF-I levels (N  43 nmol/liter) and
disappearance of signs and symptoms of active acromegaly. Octreotide therapy has been continued for more than 8 yr. The dose could be reduced
to 50 g three times daily. Discontinuation of therapy resulted in an increase of serum IGF-I levels and immediate recurrence of signs and
symptoms of active acromegaly. Dotted line shows the upper normal limit of serum IGF-I levels. B, Effect of octreotide therapy on urinary 5-HIAA
levels in a patient with a metastatic carcinoid tumor. A 66-yr-old man, operated for a metastatic carcinoid tumor of the small intestine with
abdominal lymph node metastases, hepatic metastases, and the malignant carcinoid syndrome. Urinary 5-HIAA levels were greatly elevated
(N  40 mol/24 h). Therapy with octreotide was started at a dose of 100 g three times daily. This therapy initially resulted in a reduction
of attacks of flushing and improvement of diarrhea, which was accompanied by more than 50% reduction (but not normalization) of urinary
5-HIAA levels. However, after 4–6 months of therapy, the patient developed resistance to therapy: the flushing attacks, frequency of diarrhea,
and urinary 5-HIAA levels gradually increased despite increasing the dose to 500 g three times daily. In addition, a slight increase of tumor
mass was observed. The dotted line represents the upper normal limit of urinary 5-HIAA levels.
Hofland and Lamberts • SS Receptor Internalization Endocrine Reviews, February 2003, 24(1):28–47 37
 on November 13, 2006 edrv.endojournals.orgDownloaded from 
octreotide (to 500 g three times per day) was not beneficial
in this particular patient. The potential mechanisms respon-
sible for this desensitization, as well as for the considerable
variability in the duration of the responses to octreotide
therapy, are not known at present. The relatively long time-
frame of this escape suggests mechanisms other than G pro-
tein uncoupling or internalization are involved. It has been
suggested that this loss of sensitivity of endocrine cancers to
octreotide is possibly associated with the outgrowth of clones
of tumor cells that lack sst rather than with a transient down-
regulation of these receptors (147). Moreover, it is not known
why pituitary GH-secreting pituitary adenomas do not show
tachyphylaxis to octreotide or lanreotide treatment, whereas
the majority of patients with metastatic carcinoids, VIPomas,
gastrinomas, insulinomas, and glucagonomas eventually de-
sensitize. Possibly, SS-analog treatment of patients with GH-
secreting pituitary adenomas induces an up-regulation of sst
in the GH-secreting tumor cells, whereas other types of tu-
mors display down-regulation of sst upon prolonged agonist
exposure. As will be discussed in Section III.D.1, up-regula-
tion and/or down-regulation of sst expression may be sst
subtype dependent. As has been discussed in Section I, the
majority of human sst-positive tumors express multiple sst
subtypes, often with overlapping patterns. Therefore, po-
tential tissue-specific desensitization and/or down-regu-
lation of sst subtypes or, alternatively, tissue-specific up-
regulation of the octreotide-responsive sst subtypes 2, 3,
and 5 induced by prolonged agonist treatment may ac-
count for continued responsiveness of GH-secreting pitu-
itary adenomas to SS agonists.
C. Escape from antiproliferative effects
Apart from regulating neurotransmission and secretion,
SS and its analogs may inhibit cell proliferation in normal
and tumoral tissues as well. Evidence for inhibition of tumor
cell proliferation by SS-analogs is based primarily on studies
using experimental sst-positive tumor models (2, 3). How-
ever, in a number of these studies, tumor growth is only
delayed, because after a certain treatment period the tumors
start to grow more rapidly, resulting in growth curves that
parallel tumor growth in untreated control animals, indicat-
ing escape from SS-analog therapy (148–150). In the model
of the transplantable prolactin (PRL)-secreting pituitary tu-
mor (149), we observed during the first 2 wk of treatment
with the SS-analog octreotide a significant reduction in tu-
mor growth. After 2 wk of treatment, however, tumor
growth rates in untreated and octreotide-treated animals
were parallel and not significantly different. One of the
mechanisms underlying this tachyphylaxis may be a down-
regulation of SS receptors on the tumor cells. In primary
cultures of PRL-secreting 7315b cells, an incubation with
octreotide for 1 wk inhibited both the growth and hormone
secretion in a parallel and dose-dependent fashion. How-
ever, prolonged (5 wk) continuous exposure to octreotide
(0.1 nm to 1 m) resulted in tachyphylaxis with respect to the
inhibition of PRL secretion. In a stable cell line derived from
this 7315b tumor, long-term exposure to octreotide induced
a loss of sensitivity with respect to both PRL secretion and
cell growth. This loss of sensitivity was accompanied by a
complete down-regulation of SS binding sites on the tumor
cells. In this 7315b sst-expressing tumor model, clonal selec-
tion of sst-negative cells was not the cause of desensitization,
because withdrawal of treatment from desensitized cells re-
sulted in a reappearance of sst and the sensitivity to oct-
reotide (151). A significant reduction in sst numbers induced
by octreotide treatment has also been demonstrated in Syrian
hamsters bearing transplanted insulinomas. Twice-daily in-
jections with octreotide for 3 d resulted in a dose-dependent
reduction in sst numbers on the insulinomas (2). On the other
hand, the occurrence of tachyphylaxis to treatment with SS-
analogs can be tumor cell type specific. In vivo studies by
other groups showed an increase in SS-binding on experi-
mental tumors treated with SS-analogs. Treatment of human
MKN45 gastric carcinoma xenografts in nude mice for 5 wk
with the SS-analog RC-160 significantly inhibited tumor
growth without the occurrence of an escape. Daily sc injec-
tions with RC-160 even induced a significant up-regulation
of sst in these tumors after 4–5 wk, which in this particular
tumor model may be beneficial in maintaining the inhibitory
effects on tumor growth (152). A comparable up-regulation
of sst binding sites has been demonstrated in AR4-2J pan-
creatic tumor-bearing mice, in which continuous treatment (7
d) with a low dose of octreotide, administered via octreotide-
containing osmotic minipumps, induced an increase in the
number of tumoral sst binding sites (153). In contrast to this
up-regulation of sst binding sites on pancreatic AR4-2J tu-
mors by continuous in vivo treatment with low doses of
octreotide, discontinuous (twice daily) sc injections of oct-
reotide resulted in a down-regulation of sst expression (153).
After removal of octreotide in vitro, a total recovery of [125I-
Tyr3]octreotide binding was observed within 24 h. This re-
covery was dependent on protein synthesis, making de novo
receptor synthesis necessary for the recovery process (153).
RT-PCR analysis revealed that AR4-2J cells expressed sst2
receptor mRNA only. In fact, these authors concluded that
continuous treatment with a low dose of octreotide might
improve the efficacy of long-term octreotide therapy. These
data suggest that in a single tumor model the experimental
conditions may determine whether sst2 receptors are either
down-regulated or up-regulated. In conclusion, the escape
from the tumor growth-inhibitory effects of SS-analogs sug-
gests that prolonged exposure to agonists may be due to sst
down-regulation. Moreover, in some tumor models an up-
regulation of sst expression after agonist exposure has been
observed, which might explain prolonged responsiveness to
SS-analogs. These apparently opposite experimental results
preclude making generalized conclusions with respect to the
optimal SS-analog treatment modalities that might apply to
patients with sst-positive neuroendocrine tumors. In addi-
tion, an escape from SS-analog treatment could, alterna-
tively, involve an up-regulation of binding sites that do not
recognize octreotide and/or an escape of tumor cells that do
not express octreotide-responsive sst subtypes. In the ma-
jority of the above-mentioned studies, the precise mecha-
nisms of changes in sst numbers were not studied in detail.
Therefore, it remains to be established whether the changes
in sst numbers at the cell surface are mediated via reduced
sst gene transcription, decreased stability of sst mRNAs, via
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an increased intracellular breakdown of preexistent cellular
SS receptors, or a combination of these events.
D. Mechanisms of tachyphylaxis and resistance
1. Homologous (down-)regulation of sst expression. Although
uncoupling from G proteins and internalization of SS recep-
tors cannot be fully excluded as a potential cause for reduced
sensitivity to long-term SS-analog treatment in patients with
neuroendocrine tumors, other mechanisms are more likely to
be involved. Down-regulation of cellular SS receptors may
form a long-term cause of tachyphylaxis after continuous
exposure of SS receptors to agonists. On the one hand,
chronic exposure of cultured pituitary cells to relatively high
concentrations of SS-14, SS-28, or SS-analogs reduces the
number of sst on AtT20 and 7315b pituitary tumor cells (149,
151, 154, 155). On the other hand, an up-regulation of sst
expression has been observed in GH4C1 or GH3 rat pituitary
tumor cells (156, 157). This up-regulation of SS receptors in
GH4C1 or GH3 was related to changes in sst gene expression,
rather than changes in receptor affinity. In fact, in GH3 cells,
chronic exposure with SS induces an increase of sst1, sst3, sst4,
and sst5 mRNA expression after 6–48 h of exposure, whereas
sst2 mRNA expression displayed a biphasic response, with
an increase at 2 h, a decrease at 6 h, and finally normalization
after 48 h (157). Therefore, agonist-induced down-regulation
and/or up-regulation of sst expression is time dependent
and cell type specific. In cells that do not express sst subtypes
endogenously, but were transfected with the different sst
subtype genes to overexpress the different sst subtypes, ag-
onist exposure has differential effects, depending on the sst
subtype investigated. Short-term (1 h) agonist exposure de-
creases SS-binding in CHO cells expressing the sst2A receptor
(158, 159), whereas prolonged exposure (22 h) to the peptide
induces an increased binding (54). SS binding in cells ex-
pressing sst3 and sst5 receptors was not affected by SS pre-
treatment, whereas sst4 and sst1 receptors were up-regulated
(54). Whether these sst subtype-specific responses to agonist
exposure also occur in human sst-positive tumors, which
express multiple sst subtypes, remains to be established. To
our knowledge, no such data are available at present, except
for clinical data on responsiveness and the induction of
tachyphylaxis to SS-analog therapy (see Section III.B.2). Apart
from agonist-induced changes in cell surface sst number,
tachyphylaxis of responsiveness after chronic agonist expo-
sure and/or resistance to SS-analog treatment may be in-
duced by several other potential mechanisms as well. Such
mechanisms include heterologous regulation of SS cell sur-
face numbers, heterogeneous expression of SS receptors in
human tumors, or sst gene mutations, and they are discussed
in the following paragraphs.
2. Heterologous regulation of sst expression. Apart from homol-
ogous regulation of sst expression (Section III.D.1), heterol-
ogous up- and down-regulation of SS receptors on normal
and tumorous cells has been demonstrated as well. Glu-
cocorticoids down-regulate sst numbers in GH4C1 rat pitu-
itary tumor cells. In these cells, both cortisol and dexameth-
asone reduce the specific binding of [125I-Tyr1]SS-14 by 20%
and 40%, respectively (160), probably via the inhibition of de
novo protein synthesis. Moreover, sst subtype expression in
GH4C1 cells is differentially regulated by glucocorticoids.
Short-term incubation for 2 h with dexamethasone increases
sst1 and sst2 mRNA levels, whereas sst3 mRNA levels were
unchanged. On the other hand, prolonged exposure (2 d)
with dexamethasone induced a reduction in sst1 and sst2
mRNA levels and a dramatic up-regulation of sst3 mRNA
levels. Nuclear run-on assays showed that the changes in sst1
and sst2 mRNA levels were associated with changes in sst
gene transcription rate (161). Indirect clinical evidence for the
in vivo down-regulation of tumoral SS receptors by glucocor-
ticoids was obtained from the observation that in five pa-
tients with untreated Cushings’ disease, octreotide did not
inhibit basal or CRH-stimulated ACTH levels and did not
influence cortisol levels. In vitro, however, octreotide inhib-
ited CRH-stimulated ACTH secretion by human cortico-
troph adenoma cultures, whereas this inhibitory effect was
abolished by hydrocortisone pretreatment (162). Estrogens
have been shown to stimulate sst expression in pituitary
(tumor) cells (163–165) in vitro and in vivo. Chronic estrogen
treatment up-regulates sst2 receptor mRNA expression in the
anterior pituitary gland in vivo (166). Considerably less in-
formation is available regarding the heterologous regulation
of sst expression in nonpituitary-derived cell systems. In
breast cancer cell lines, estrogen stimulates steady state
mRNA levels (167). A 5.3-kilobase pairs (kb) 5-flanking re-
gion of the hsst2 gene, lacking TATA and CCAAT boxes, is
the active promotor in estrogen receptor-positive breast can-
cer cell lines (168). In agreement with these observations,
Kimura et al. (169) recently demonstrated that estrogen reg-
ulated promotor activity of a 5-kb 5-untranslated region of
the rat sst2 gene, lacking TATA and CCAAT boxes (169). In
concordance with the findings in pituitary-derived cells,
dexamethasone may cause down-regulation of sst numbers
without changing receptor affinity in AR42J rat pancreatic
acinar carcinoma cells (170). Thyroid hormones may regulate
sst expression as well. In TtT-97 tumors, which represent an
in vivo murine thyrotropic model not expressing any sst
subtype mRNA or protein, thyroid hormone treatment in-
duces specific up-regulation of sst1 and sst5 mRNAs and high
affinity sst binding sites in the tumors (171). Taken together,
these data demonstrate that sst subtype expression can be
influenced by different steroids and hormones in a time-
specific and receptor subtype-specific manner. It is not es-
tablished, however, whether treatment of patients with, for
example, glucocorticoids or antiestrogens may influence sst
expression and thus responsiveness to SS in vivo as well.
Apart from a regulatory effect of glucocorticoids and estro-
gens on sst expression, it is also likely that such agents di-
rectly influence the responsiveness of tumor cells to SS ago-
nists. Indeed, breast cancer cells have been shown to respond
better to the cytotoxic effect of octreotide in the presence of
the antiestrogen tamoxifen (172).
3. Resistance to SS agonists
a. Heterogeneity of tumoral sst expression. Certain subgroups
of human sst-positive tumors express sst subtypes on the
basis of their differential binding of SS and SS-analogs. The
sst autoradiographic studies showed the absence of binding
of [125I-Tyr3]octreotide in a small subgroup of human insu-
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linomas, carcinoids, pituitary adenomas, and meningiomas,
in 50% of MTCs, and in all sst-positive ovarian cancers,
whereas in the same tumors binding sites for iodinated-
[Tyr11]SS-14 or [LTT]SS-28 were present (23–25). This differ-
ential binding between octreotide on the one hand and SS-
14/SS-28 ligands on the other hand, in insulinomas and other
subgroups of sst-positive tumors, suggests that resistance to
octapeptide SS-analogs may be due to the absence of specific
sst subtypes that bind these analogs with high affinity, but
also indicates that novel sst subtype-selective analogs can be
developed for the treatment of patients with tumors carrying
sst of this particular subtype(s). Although certain human
sst-positive tumors lack particular sst subtypes with high
affinity for octapeptide SS-analogs (Table 1), some tumors
have been demonstrated to express a nonhomogenous dis-
tribution of SS receptors (23–25). A nonhomogenous distri-
bution of sst has been found in a subset (3 of 10) of human
GH-secreting pituitary adenomas (173), as well as in rare
cases of carcinoid tumors (23). Moreover, in more than 50%
of breast cancer specimens, sst expression displayed a non-
homogenous distribution, i.e., both sst-positive and sst-
negative tumor regions within individual sst-positive tu-
mors (174). One rare case of a human carcinoid tumor has
been described in which sst1 and sst2 mRNA were clearly
localized in different tumor regions (28). In such cases, re-
sistance to SS-analog therapy, after an initial response, may
be due to the outgrowth of sst (sst2)-negative tumor cell
clones, which in fact may still express sst, albeit of the sub-
type to which the current generation of octapeptide SS-
analogs do not bind.
b. SS receptor gene mutations. To date, relatively few data are
available with respect to sst-gene mutations leading to a loss
of sst function. One study addressed this issue so far in
COR-L103 small cell lung cancer cells (175). Sequence anal-
ysis of the sst2 gene demonstrated a point mutation in codon
188 of TGG for tryptophan to TGA for a stop codon causing
a loss of 182 C-terminal amino acid residues in sst2, resulting
in the absence of sst2 expression in the plasma membrane of
COR-L103 cells. The nucleotide sequences of the sst3 and sst4
genes, which were also expressed in these cells, were normal.
In a series of 19 human GH-secreting pituitary adenomas
with variable sensitivity to SS-analog treatment in vivo, the
sst2 and sst5 genes were found to possess intact coding se-
quences (176). Moreover, no mutations affecting the sst2 pro-
tein were detected in a series of 15 GH-secreting pituitary
adenomas (177). These data suggest that mutations in these
sst subtypes do not form the basis for resistance of tumoral
GH secretion to SS-analogs. Ballare et al. (178) recently de-
scribed a germ line mutation (Arg240Trp) in the sst5 gene in
an acromegalic patient resistant to SS-analog treatment. This
mutation results in decreased sensitivity to the inhibitory
effect of SS on adenylate cyclase activity, whereas cells ex-
pressing the mutant sst5 displayed increased proliferation
and increased MAPK activity, compared with wt cells. These
data suggest that this mutation in sst5 abrogated the anti-
proliferative action by SS and activated mitogenic pathways.
Nevertheless, such mutations appear to be very rare. Finally,
in none of a series of 43 neuroblastoma tumors were muta-
tions in the sst2 gene detected by PCR-based single-stranded
conformation polymorphism/heteroduplex analysis (179).
Mutations in other sst subtypes that may cause this resistance
cannot be excluded, however. Moreover, other causes such
as sst density and/or the above-discussed mechanisms of
resistance (summarized in Table 4) may play a role as well.
c. Miscellaneous potential causes of resistance to SS-analogs.
Antibodies to octreotide that develop in patients treated with
this analog (138, 180–182) seem not to be an important cause
of escape from therapy with SS-analogs, because continued
efficacy of octreotide treatment has been documented in two
acromegalic patients who had antibodies to octreotide (181).
G protein mutations, particularly mutations in Gs, have
been shown to be associated with overproduction of hor-
mones by pituitary-derived hormones, as well as with pitu-
itary hyperplasia (183). In a subgroup of patients with GH-
secreting pituitary adenomas, high basal adenylyl cyclase
activity and poor responsiveness to stimulatory agents such
as GH-releasing hormone suggested constitutive activation
of the adenylyl cyclase cascade in the tumor cells. A con-
siderable number of these tumors indeed contained an ac-
tivating mutation in Gs (183), which correlates with a higher
sensitivity to SS agonists. An increase in sst2 mRNA does not
seem to account for this increased sensitivity (184). However,
mutations in inhibitory G proteins are rare, and mutations in
Gi2, to which sst2 is capable of associating (185), have only
been described in small numbers of adrenal cortical tumors
(27%) and ovarian tumors (30%; Ref. 186). It appears there-
fore, that resistance to SS-analog therapy due to a mutation in
inhibitory G proteins coupled to sst is not very likely to occur.
E. New developments
As described in Section III.D.3, one of the causes for re-
sistance to therapy with the current generation of octapep-
tide SS-analogs may be the absence or low expression of sst2
receptors by the tumor cells. The question then arises: What
might be the role of other sst subtypes as a target for therapy
with novel SS-analogs? Functional evidence for the existence
of sst subtypes comes from studies using human fetal pitu-
itary cell cultures in which SS regulates GH and TSH secre-
tion by both sst2 and sst5, and PRL secretion mainly by sst2
(74). In recent years, many new sst selective analogs have
been synthesized. Using primary cultures of human GH-
secreting pituitary adenomas, Melmed and co-workers (75)
demonstrated that combinations of sst2- and sst5-selective
TABLE 4. Potential mechanisms of tachyphylaxis and resistance to
SS-analog therapy in patients with sst-positive tumors
1. Down-regulation: decrease in the number and/or affinity of SS
receptors
2. Desensitization: decrease in responsiveness due to receptor
uncoupling from second messenger activation
3. Nonhomogeneous expression of SS receptors in tumors:
outgrowth of sst-negative cell clones
4. Resistance due to the absence of sst subtypes with high affinity
for octapeptide SS-analogs
5. Resistance due to tachyphylaxis of the inhibitory effect of SS-
analogs on indirect tumor growth-promoting mechanisms (i.e.,
GH or gastrin secretion)
6. Mutations in sst genes leading to absence of functional receptor
proteins
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compounds decreased GH secretion significantly more than
the single compounds alone. In addition, in PRL-secreting
primary tumor cell cultures, PRL secretion was preferentially
inhibited by sst5-selective analogs, whereas sst2-selective an-
alogs were ineffective. Even more exciting are recent studies
using a bispecific sst analog with high affinity binding to both
sst2 and sst5 receptors. This compound, BIM-23244 (Table 1),
was quite effective in inhibiting GH secretion in vitro by a
series of five octreotide partially responsive tumors. These
tumors turned out to have 9-fold lower sst2 mRNA levels and
approximately 7-fold higher sst5 mRNA levels, compared
with a group of octreotide-sensitive tumors. The same com-
pound also inhibited PRL release by five mixed GH-PRL-
secreting pituitary adenomas (187). Thus, apart from highly
sst-selective analogs, there may be a place for new sst bispe-
cific analogs in the treatment of pituitary adenomas resistant
to sst2 agonists. More recently, a SS peptidomimetic, named
SOM230, with high affinity for sst1, sst2, sst3, and sst5 recep-
tors (Table 1) has been shown to have a much higher efficacy
in lowering normal plasma IGF-I levels in rats, compared
with the effects of the sst2-selective analog octreotide (188).
Long-term (weeks to months) continuous, as well as discon-
tinuous, treatment with octreotide in rats is known to result
in a loss of the inhibitory effect of the drug on circulating GH
and IGF-I levels (148, 149, 189). The potent inhibitory effect
of SOM230 on IGF-I levels, showing no signs of loss of its
inhibitory effect during a period of 126 d of continuous
infusion, could be explained by a 40-fold increase in the
affinity for sst5 receptors, as compared with octreotide in
combination with the key role that sst5 plays in controlling
GH release (75, 187). SOM230 has a very long terminal elim-
ination half-life of 23 h in rats, compared with octreotide (2
h), and no obvious adverse side effects, including changes in
glucose levels, over the 126-d period of treatment, and it is
currently under evaluation in phase I trials (188). Moreover,
sst subtypes may form homo- or heterodimers (56, 58) or may
heterodimerize with other G protein-coupled receptors such
as the dopamine D2 receptor (60) or the opioid receptor
MOR-1 (59), resulting in a novel receptor state with prop-
erties distinct from the individual receptors in terms of en-
hanced internalization, reduced agonist-induced desensiti-
zation, and functional activity. These new fundamental
insights into receptor function will help us to explain the
observed differences in the development of tachyphylaxis
not only between patients with different tumor types, but
also among patients with the same type of neuroendocrine
tumor but with different sst subtype expression patterns. It
is a challenge to evaluate whether these new bispecific or
more universal SS-analogs are indeed effective in tumors
resistant to the current clinically available compounds as
octreotide and lanreotide, as well as to investigate whether
such new compounds can prevent neuroendocrine tumors
from tachyphylaxis to treatment. Apart from new analogs
with a broader sst binding profile, a hybrid SS-dopamine
molecule has also been recently synthesized. This molecule,
BIM-23A387, retained high affinity binding to both sst2 and
D2 receptors and had a tremendous enhanced potency on
GH and PRL release by primary cultures of human pituitary
adenoma cells, compared with sst2- and D2-specific analogs,
alone or in combination (190). This significant enhanced po-
tency, however, could not be explained on the basis of the
binding affinity of the compounds for sst2 and D2 receptors
(190). The mechanism by which this molecule exerts its po-
tent action is unknown but strengthens the observations that
processes like heterodimerization of receptors indeed have
functional implications.
F. Conclusions
The induction of tachyphylaxis of responsiveness to SS-
agonists has been demonstrated in a variety of sst-positive
cell systems. The time-frame of the occurrence of tachyphy-
laxis in vivo on normal hormone secretion is relatively rapid
(hours to days), whereas escape from therapy with SS-
analogs in patients with sst-positive tumors or in experi-
mental models of sst-positive tumors generally occurs after
prolonged exposure to SS agonists (weeks to years). This
relative late induction of tachyphylaxis of responsiveness
suggests that sst down-regulation, rather than rapid pro-
cesses like G protein uncoupling and/or receptor internal-
ization are involved. Moreover, escape from SS-analog ther-
apy could involve the outgrowth of tumor cell clones lacking
the expression of sst subtypes to which the currently clini-
cally used octapeptide analogs bind with high affinity. The
development of novel sst subtype-selective and nonselective
analogs, as well as chimeric compounds, could be of interest
as potential new treatment modalities for resistant tumors.
The only group of tumors that show no signs of desensi-
tization to treatment with SS-analogs are GH-secreting
pituitary adenomas. In SS-analog-sensitive patients with
GH-secreting pituitary adenomas, circulating GH and IGF-I
concentrations can be effectively suppressed, even during
many years of treatment with these compounds. The under-
lying mechanisms for this difference in developing tachy-
phylaxis to SS-analog treatment between GH-secreting pi-
tuitary adenomas on the one hand, and other types of
neuroendocrine tumors on the other hand, have not yet been
elucidated but could involve the differential expression of sst
subtypes, a tissue-specific desensitization, and/or down-
regulation of sst subtypes, or alternatively, tissue-specific up-
regulation of SS-analog responsive sst subtypes by prolonged
agonist treatment resulting in continued responsiveness.
In conclusion, clinical observations clearly demonstrate
tachyphylaxis and/or resistance to SS-analog treatment in
patients with neuroendocrine tumors, but the direct funda-
mental evidence explaining the mechanisms involved is cur-
rently weak.
IV. Summary
During the past decade, novel insights into the physio-
logical and pathophysiological role of SS and its receptors
have been developed. Although in the mid-1980s it was
debated whether or not SS was internalized by sst-expressing
cells, recent studies have now clearly demonstrated that SS
and SS-analogs are efficiently internalized via a rapid process
of agonist-induced receptor-mediated endocytosis. More-
over, in 1989 the technique of sst scintigraphy to visualize
sst-positive tumors in humans was developed, and the con-
cept of the radiotherapeutic use of radioisotope-coupled SS-
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analogs, i.e., peptide receptor radionuclide therapy, was in-
troduced. Finally, in the beginning of the 1990s, five sst
subtypes were cloned and characterized, and the expression
of these subtypes has been studied in both normal and tu-
moral sst-expressing tissues. Taking these discoveries to-
gether, several new questions can be raised. These include:
1) Which sst subtypes that are expressed in human sst-
positive tumors determine (un)responsiveness to octapep-
tide SS-analogs such as octreotide or lanreotide, and is there
a role for novel sst subtype selective SS-analogs? 2) Which sst
subtypes are involved in receptor-mediated endocytosis of
radiolabeled SS-analogs and form the basis for targeted ra-
diotherapy or chemotherapy using SS-analogs coupled with
radioisotopes or chemotherapeutic compounds, respec-
tively? and 3) What is the role of the individual sst subtypes
in determining responsiveness, as well as tachyphylaxis of
responsiveness of sst-positive cells upon agonist exposure?
In this review, the current knowledge of the clinical conse-
quences of agonist-induced sst internalization for treatment
for sst-targeted radiotherapy or chemotherapy are discussed,
as well as the different mechanisms that could play a role in
tachyphylaxis and/or resistance to SS-analog therapy in pa-
tients with neuroendocrine tumors.
The individual sst subtypes differentially internalize SS-
(analogs). The sst1 receptors show low agonist-induced in-
ternalization, whereas sst2, sst3, sst4, and sst5 are more effi-
cient in this respect. The predominant expression of sst2
receptors in most human sst-positive neuroendocrine tumors
and the efficiency of sst2 receptors to undergo agonist-
induced internalization is very important for the radiother-
apeutic application of radiolabeled octapeptide SS-analogs.
In vitro studies have demonstrated that sst2-expressing
tumor cell lines, as well as primary cultures of human
tumors, internalize radiolabeled SS-analogs such as [111In-
DTPA0]octreotide, [90Y-DOTA0,Tyr3]octreotide, and [90Y-
DOTA]lanreotide. Preclinical studies using experimental
tumor models have now demonstrated that tumor growth
can be inhibited by administration of radiopharmaceutical
compounds as [111In-DTPA0]octreotide and [90Y-DOTA0,Tyr3]-
octreotide. Clinical trials have already demonstrated promising
effects using these radiopharmaceuticals, as well as of [90Y-
DOTA-lanreotide], on tumor size in patients with advanced
sst-positive neuroendocrine tumors. Finally, the concept of tar-
geted chemotherapy to deliver chemotherapeutic compounds
selectively to sst-positive tumor cells, thereby reducing their
toxicity, has now been validated using newly developed cyto-
toxic SS-analogs in experimental mouse and rat models of hu-
man pancreatic, breast, prostate, ovarian, and small cell lung
cancer.
The presence of sst2 receptors in tumors is a prerequisite
for sensitivity of inhibition of tumor-related hormonal hy-
persecretion to treatment with octapeptide SS-analogs. The
successful clinical application of SS-analogs such as oct-
reotide and lanreotide in the treatment of hormonal hyper-
secretion in patients with GH-secreting pituitary adenomas
and islet cell or carcinoid tumors is caused by the predom-
inant expression of sst2 receptors in these tumors. On the
other hand, novel sst subtype-selective analogs, as well as
bispecific and more universal agonists, have been synthe-
sized now and were demonstrated to be effective in the in
vitro inhibition of hormone secretion of sst-positive tumors
that do not express sst2 receptors. Patients with sst-positive
tumors also show considerable variability in their respon-
siveness to treatment with SS-analogs. Patients with GH-
secreting pituitary adenomas do not show desensitization to
treatment with SS-analogs, whereas patients with islet cell or
carcinoid tumors often demonstrate tachyphylaxis to treat-
ment. The occurrence of tachyphylaxis upon treatment with
SS-analogs is highly variable. Some patients escape very
rapidly, whereas others show tachyphylaxis only after sev-
eral years of treatment. Nevertheless, despite the increasing
fundamental knowledge on the role of individual sst sub-
types in agonist-induced internalization and/or desensiti-
zation of sst subtypes, as well as in agonist-induced, sst
subtype-specific regulation of sst expression and receptor
homo- and heterodimerization, the direct fundamental evi-
dence for the observed differences between patients with
neuroendocrine tumors in the development of tachyphylaxis
to SS-analogs is currently weak and requires further studies.
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